Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Price Target at $5.57

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) have been given an average recommendation of “Moderate Buy” by the nine analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $5.57.

A number of research firms have weighed in on MRSN. William Blair began coverage on Mersana Therapeutics in a report on Thursday, February 6th. They issued an “outperform” rating for the company. Citigroup began coverage on Mersana Therapeutics in a report on Friday, November 15th. They issued a “buy” rating and a $5.00 price target for the company. Finally, Wedbush restated an “outperform” rating and issued a $4.00 price target (down previously from $7.00) on shares of Mersana Therapeutics in a report on Friday, January 10th.

Mersana Therapeutics Stock Up 1.0 %

Shares of NASDAQ:MRSN opened at $0.53 on Friday. The company has a debt-to-equity ratio of 13.35, a quick ratio of 2.35 and a current ratio of 2.35. Mersana Therapeutics has a 1 year low of $0.49 and a 1 year high of $6.28. The stock has a market capitalization of $65.87 million, a P/E ratio of -0.87 and a beta of 1.39. The stock has a 50-day simple moving average of $0.97 and a 200-day simple moving average of $1.60.

Institutional Investors Weigh In On Mersana Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. US Bancorp DE acquired a new stake in shares of Mersana Therapeutics during the 3rd quarter valued at approximately $31,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Mersana Therapeutics during the 3rd quarter valued at approximately $34,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Mersana Therapeutics during the 4th quarter valued at approximately $37,000. Intech Investment Management LLC acquired a new stake in shares of Mersana Therapeutics during the 3rd quarter valued at approximately $52,000. Finally, Quarry LP acquired a new stake in shares of Mersana Therapeutics during the 3rd quarter valued at approximately $57,000. 93.92% of the stock is owned by institutional investors and hedge funds.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.